











































<section-header><section-header><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item><list-item>



















16























Initial Results		ASSAULT AVAILUE CALTE DARAGENT Intraoperative Tissue Identi Evaporative Ionization Mass alls stag ¹ via data fais faisk ¹ , and show and stag ¹ via data fais faisk ¹ . And show are yet behaves ¹ zone have	Science Translational Medicine MAAA	
Organ	Tumor type	Number of patients	Number classified	Correct classification
Gastric	Adenocarcinoma	37	37	100%
	Mucinous	14	14	100%
Large intestine/col	on Adenocarcinoma	85	85	98.24%
Large intestine rectum, border	Adenocarcinoma	72	72	100%
Liver	HCC	14	14	100%
	Metastasis	38	38	100%
Lungs	Adenocarcinoma	52	52	100%
	SCC	16	16	100%
	Other	9	6	76.67%
Breast	Lobular	23	18	100%
Brain	Mixed	43	23	100%

Overall 525 interventions, tumor was identified in 417 cases, 2 misclassifications (other type of cancer)

Imperial College





































671.47	673.48	699.5	713.51	714.51
PA(16:0/18:2) M-H	PA(16:0/18:1) M-H	PA(18:1/18:1) M-H	PE(20:2/18:1) M-H	PE(16:0/18:2) M-H PE(16:1/18:1) M-H
716.52	735.47	742.54	744.55	747.51
PE(18:0/16:1) M-H PE(16:0/18:1) M-H	PA(P-20:0/20:4) M-H PA(P-20:1/20:3) M-H	PE(18:0/18:2) M-H PE(18:1/18:1) M-H	PE(18:0/18:1) M-H	PA(18:1/22:5) M-H PA(16:1/18:1) M-H PA(18:2/22:4) M-H PA(18:0/16:1) M-H
766.54	768.55	770.57	772.58	
PE(18:0/20:4) M-H	PA(18:0/18:2) M-H PE(18:0/20:3) M-H	PE(18:0/20:2) M-H	PE(18:0/20:1) M-H PE(22:1/16:0) M-H	







33



	Destative Mala sector				
m/z	structure	P value	Cancer	Adenoma	Normal
	633.465PA(31:0)	0.0001			
	886.565PS (44:6)	1.11E-16			
	886.565PS(44:8)	1.11E-16			
	888.75PS(41:0)	1.38E-12			
	702.625Cer(D18:0/H24:0)	2.28E-11			
	775.545PG(36:1)	0.0001			
	673.485PA(34:0)	3.33E-16			
	642.495GlcCer(30:1)	2.47E-12			
	880.665PS (43:4)	1.86E-07			
	699.505PA	1.12E-07			
	710.485PE(34:4)	6.73E-08			
	718.615Cer(T18:0/24:0(2OH))	9.30E-10			
	653.4951,2-DG(36:3)	0.0002			
	797.535PG(38:4)	0.004			
	864.675Plasmalogen	0.0004			
	891.725TG (54:0)	1.63E-08			



	5	,					
	Spectra	Spectra n = Accuracy		True	False	False	AUC
			Positive	Negative	Positive	Negative	
Diagnostic markers All		<u> </u>					
Cancer vs. NAM	220	90.5%	86.7%	92.4%	13.3%	7.6%	0.96
Cancer vs. Adenoma	89	94.4%	78.6%	97.3%	2.7%	21.4%	0.99
Adenoma vs. NAM	159	97.5%	85.7%	98.6%	1.4%	98.6%	0.99
Histological subtype	75	90%	94.2%	83.3%	16.7%	5.8%	0.96
(Mucinous vs. Adenocarcinoma)							
Prognostic performance – whole model							
Tumour differentiation	183	83.1%	68.3%	87.3%	12.7%	31.7%	0.88
(Mod vs. poor)							
Tumour budding	234	78.2%	80.6%	74.4%	25.6%	19.4%	0.87
LVI	234	73.9%	71.6%	75.3%	24.7%	28.4%	0.83
EMVI	234	73.5%	65.3%	77.2%	22.8%	34.7%	0.81
+ve Nodes	234	77.4%	69.0%	81.0%	19.0%	31.0%	0.81
Rectal cancer prognostic factors							
Differentiation (Mod vs. poor)	84	94.4%	78.6%	98.2%	1.8%	21.4%	0.99
Tumour Budding	84	84.5%	88.1%	70.6%	29.4%	11.9%	0.82
LVI	84	71.4%	72.4%	30.8%	69.2%	27.6%	0.75
EMVI	84	96.4%	85.7%	98.6%	14.3%	1.4%	0.98
+ve Nodes	84	92.9%	83.3%	94.4%	5.6%	16.7%	0.92
LCRT vs. None	75	96%	95.7%	96.2%	3.8%	4.3%	0.99
			1000/	10001	00/	0.01	4





























Thank you - Acknowledgements Prof. Jeremy Nicholson Dr Julia Blalog Prof. Zoltan Takats Dr. Julia Denes Prof. Ara Darzi Dr James McKenzie Dr. Sabine Guenther Prof. Elaine Holmes Dr. Nicole Strittmatter Dr. Cristina Guallar Hoyas Prof. Rob Goldin Mr. Daniel Leff Mr. Edward St. John Dr. Ottmar Golf Dr. Verena M Horneffer-van der Sluis Mr. Reza Mirnezami Mss. Laura Muirhead Dr. Emrys Jones Dr. Balazs Dezso Mr. Babar Vaqas Dr. Laszlo Sasi-Szabo Mr. David Phelps Dr. Steven Pringle Dr. James Alexander Dr. Kirill Veselkov Dr. Mike Morris Dr. Tamás Szaniszló Dr. Dória, Luísa Dr. Louise Gildea Dr. Merja Rossi Dr. Dániel Szalay Dr. Lajos Gödörházi Dr. Louise Gildea Dr. Andor Rozsnyai Waters **NIHR Imperial BRC** Imperial College Translating research into patient benefits THE SCIENCE OF WHAT'S POSSIBLE."